- Price
- $39.00
- Day
- +0.72%
- Mkt Cap
- $1.98B
- 52W Range
- $25.36 – $43.18
- Volume
- 864.5K
- Beta
- 1.25
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
On July 31, 2026, AtriCure Inc (ATRC) shares fell 6.0% today, bringing the current price to $37.76. This price is within a 52-week range of $25.36 to $43.18, re
Read full article
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
Read full article
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu.
Read full article
AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive ablation.
Read full article
AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago.
Read full article
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read full article